BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Trastuzumab rezetecan readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Trastuzumab rezetecan\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06015048-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Trastuzumab rezetecan: Phase 1/2 readout est. (NCT06015048)
DESCRIPTION:Trastuzumab rezetecan\, phase 1/2.\nStudy: A Trial of SHR-A1811
  Combined With Other Antitumor Therapies in Advanced Solid Tumors.\nEstima
 ted primary completion: November 2026. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06015048
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05482568-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Trastuzumab rezetecan: Phase 1/2 readout est. (NCT05482568)
DESCRIPTION:Trastuzumab rezetecan\, phase 1/2\, Non-Small Cell Lung Cancer.
 \nStudy: A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or 
 SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer\nEstimated p
 rimary completion: December 2026. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05482568
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06840002-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Trastuzumab rezetecan: Phase 1/2 readout est. (NCT06840002)
DESCRIPTION:Trastuzumab rezetecan\, phase 1/2\, Ovarian Cancer.\nStudy: A C
 linical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensiti
 ve Recurrent Ovarian Cancer\nEstimated primary completion: December 2026. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-rezetecan
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT068
 40002
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05924256-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT05924256)
DESCRIPTION:Trastuzumab rezetecan\, phase 2.\nStudy: A Phase II Study of Ad
 vanced Salivary Gland Carcinoma Based on Molecular Typing\nEstimated prima
 ry completion: 30 December 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05924256
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06413745-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT06413745)
DESCRIPTION:Trastuzumab rezetecan\, phase 2.\nStudy: Phase II Clinical Stud
 y of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally
  Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer\nEstim
 ated primary completion: 31 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06413745
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05076682-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT05076682)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Breast Cancer.\nStudy: Revers
 e Triple Negative Immune Resistant Breast Cancer\nEstimated primary comple
 tion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/trastuzumab-rezetecan#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05076682
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05424835-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Trastuzumab rezetecan: Phase 3 readout est. (NCT05424835)
DESCRIPTION:Trastuzumab rezetecan\, phase 3\, Breast Cancer.\nStudy: A Tria
 l of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Po
 sitive\, Unresectable and/or Metastatic Breast Cancer Subjects Previously 
 Treated With Trastuzumab and Taxane\nEstimated primary completion: 31 Dece
 mber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzuma
 b-rezetecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05424835
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07305246-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07305246)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Breast Cancer.\nStudy: Clinic
 al Study of SHR-A1811 With or Without Letrozole in Neoadjuvant Therapy for
  Early-Stage HR-Positive\, HER2-Low Breast Cancer\nEstimated primary compl
 etion: March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tr
 astuzumab-rezetecan#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07305246
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06547736-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT06547736)
DESCRIPTION:Trastuzumab rezetecan\, phase 2.\nStudy: Exploratory Platform R
 esearch on Precision Therapy of Advanced Pancreatic Cancer\nEstimated prim
 ary completion: March 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/trastuzumab-rezetecan#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06547736
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07416253-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07416253)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, HER2-Positive Breast Cancer.\
 nStudy: Trastuzumab Rezetecan vs Trastuzumab Deruxtecan in the Neoadjuvant
  Treatment of HER2 Positive Breast Cancer\nEstimated primary completion: M
 arch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzuma
 b-rezetecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07416253
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06433609-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT06433609)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Study of ADCs Combined With Adebrelimab in HER2-negative Ad
 vanced Breast Cancer\nEstimated primary completion: March 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06433609
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07704177-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270415
DTEND;VALUE=DATE:20270416
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07704177)
DESCRIPTION:Trastuzumab rezetecan\, phase 2.\nStudy: Phase II Study of Tras
 tuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER
 2-Positive/Low-Expression Biliary Tract Cancer\nEstimated primary completi
 on: 15 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tr
 astuzumab-rezetecan#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07704177
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07670273-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270429
DTEND;VALUE=DATE:20270430
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07670273)
DESCRIPTION:Trastuzumab rezetecan\, phase 2.\nStudy: Phase II Study of Tras
 tuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line T
 herapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer\nEstimated
  primary completion: 29 April 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07670273
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06828354-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Trastuzumab rezetecan: Phase 3 readout est. (NCT06828354)
DESCRIPTION:Trastuzumab rezetecan\, phase 3\, Ovarian Cancer.\nStudy: A Stu
 dy of SHR-A1811 in Subjects With Ovarian Cancer\nEstimated primary complet
 ion: May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastu
 zumab-rezetecan#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06828354
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06973525-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT06973525)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, HER2-Positive Breast Cancer.\
 nStudy: This Study Aims to Optimize Neoadjuvant Therapy for HER2-positive 
 Breast Cancer by Implementing a Dynamic Monitoring-guided Treatment Strate
 gy.\nEstimated primary completion: 31 May 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06973525
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07275242-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Trastuzumab rezetecan: Phase 1 readout est. (NCT07275242)
DESCRIPTION:Trastuzumab rezetecan\, phase 1.\nStudy: A Clinical Study of SH
 R-A1811(sc) Subcutaneous Injection in Patients With Solid Tumor\nEstimated
  primary completion: June 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07275242
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06975475-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT06975475)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Breast Cancer.\nStudy: SHR-A1
 811 and THPy in First or Second Line for HER2 Positive Advanced Breast Can
 cer Brain Metastases\nEstimated primary completion: 1 June 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06975475
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06975462-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT06975462)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: A Phase II Study of SHR-A1811 Combined With Radiotherapy in
  HER2-positive and HER2-low Breast Cancer Brain Metastases\nEstimated prim
 ary completion: 1 June 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/trastuzumab-rezetecan#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06975462
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06123494-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Trastuzumab rezetecan: Phase 3 readout est. (NCT06123494)
DESCRIPTION:Trastuzumab rezetecan\, phase 3\, Gastric Cancer.\nStudy: SHR-A
 1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal J
 unction Adenocarcinoma After Progression on or After First-line Anti-HER2 
 Therapy-containing Regimen\nEstimated primary completion: 30 June 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-rezetecan#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06123
 494
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07528898-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07528898)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, HER2-Positive Breast Cancer.\
 nStudy: Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Br
 east Cancer: An Exploratory Clinical Study.\nEstimated primary completion:
  July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzum
 ab-rezetecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07528898
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07630077-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07630077)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: Trastuzumab Rezetecan(SHR-A1811) Combined With Ivonescimab (AK112) 
 in Locally Advanced or Metastatic Non-small Cell Lung Cancer Harboring HER
 2 Gene Abnormalities\nEstimated primary completion: 1 July 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07630077
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07778745-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07778745)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: A Prospective Phase II Clinical Trial Evaluating the Efficacy and S
 afety of Adebrelimab in Combination With Trastuzumab Rezetecan for Patient
 s With Stage III Unresectable HER2-Positive NSCLC\nEstimated primary compl
 etion: 30 August 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/trastuzumab-rezetecan#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07778745
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07309770-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270911
DTEND;VALUE=DATE:20270912
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07309770)
DESCRIPTION:Trastuzumab rezetecan\, phase 2.\nStudy: Trastuzumab Rezetecan 
 in Advanced Solid Tumors Refractory to Standard Therapies\nEstimated prima
 ry completion: 11 September 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07309770
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07140393-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Trastuzumab rezetecan: Phase 1/2 readout est. (NCT07140393)
DESCRIPTION:Trastuzumab rezetecan\, phase 1/2.\nStudy: A Study of HRS-4508 
 in Combination With Other Anti-tumor Therapy for Solid Tumor\nEstimated pr
 imary completion: October 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07140393
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07129018-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07129018)
DESCRIPTION:Trastuzumab rezetecan\, phase 2.\nStudy: Trastuzumab Rezetecan 
 Combined With Pertuzumab and Iparomlimab and Tuvonralimab for Biliary Trac
 t Cancer\nEstimated primary completion: November 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07129018
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07102901-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07102901)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Gastric Cancer.\nStudy: Safet
 y and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastr
 ic or Gastro-oesophageal Junction Adenocarcinoma\nEstimated primary comple
 tion: December 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 trastuzumab-rezetecan#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07102901
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07281209-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07281209)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: A Study of SHR-A1811 Combined With Adebelimumab as Neoadjuvant Ther
 apy for Resectable HER2-Altered Non-Small Cell Lung Cancer\nEstimated prim
 ary completion: December 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07281209
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05671822-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT05671822)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Gastric Cancer.\nStudy: Ph1b/
 2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced H
 ER2 Expression Gastric Cancer\nEstimated primary completion: December 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-rezetec
 an#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5671822
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07196774-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trastuzumab rezetecan: Phase 3 readout est. (NCT07196774)
DESCRIPTION:Trastuzumab rezetecan\, phase 3\, HER2-Positive Breast Cancer.\
 nStudy: A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoa
 djuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast
  Cancer\nEstimated primary completion: December 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07196774
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07307287-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07307287)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early 
 or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective
 \, Open-Label\, Phase II Study\nEstimated primary completion: 31 December 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-rez
 etecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07307287
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07489703-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07489703)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC\nEstima
 ted primary completion: 31 December 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07489703
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05749588-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT05749588)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Breast Cancer.\nStudy: FUSCC 
 Refractory TNBC Platform Study (FUTURE2.0)\nEstimated primary completion: 
 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tra
 stuzumab-rezetecan#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05749588
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05582499-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT05582499)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, HER2-Positive Breast Cancer.\
 nStudy: Fudan University Shanghai Cancer Center Breast Cancer Precision Pl
 atform Series Study- Neoadjuvant Therapy\nEstimated primary completion: 31
  December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trast
 uzumab-rezetecan#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05582499
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07817654-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07817654)
DESCRIPTION:Trastuzumab rezetecan\, phase 2.\nStudy: Trastuzumab Combined W
 ith Retlirafusp Alfa in Treating HER2（Human Epidermal Growth Factor Rece
 ptor 2） 2+/3+ Gastric/Gastroesophageal Junction Adenocarcinoma After Fir
 st-line Systemic Therapy Failure\nEstimated primary completion: 31 Decembe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-r
 ezetecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07817654
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07466927-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280115
DTEND;VALUE=DATE:20280116
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07466927)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Study of Multi-mode Thermal Therapy Combined With Immunothe
 rapy In Patients With HER2-negative Breast Cancer With Liver Metastases\nE
 stimated primary completion: 15 January 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07466927
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07355764-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280130
DTEND;VALUE=DATE:20280131
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07355764)
DESCRIPTION:Trastuzumab rezetecan\, phase 2.\nStudy: MA-CRC-II-016 SHR-1811
 \nEstimated primary completion: 30 January 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07355764
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07383818-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07383818)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Breast Cancer.\nStudy: Neoadj
 uvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/
 HER2-low Breast Cancer (NEOTORCH-BREAST 08)\nEstimated primary completion:
  1 February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tra
 stuzumab-rezetecan#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07383818
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07466303-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07466303)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Breast Cancer.\nStudy: Serplu
 limab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Tripl
 e-Negative Breast Cancer\nEstimated primary completion: 1 February 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-rezetecan#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0746
 6303
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07111832-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Trastuzumab rezetecan: Phase 3 readout est. (NCT07111832)
DESCRIPTION:Trastuzumab rezetecan\, phase 3\, Breast Cancer.\nStudy: A Clin
 ical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer\
 nEstimated primary completion: March 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07111832
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07776171-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07776171)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Ovarian Cancer.\nStudy: Trast
 uzumab Rezetecan and Carboplatin ± Bevacizumab Versus Investigator's Choi
 ce Chemotherapy in Patients With Platinum-sensitive Recurrent Ovarian Canc
 er\nEstimated primary completion: 30 March 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07776171
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06788197-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Trastuzumab rezetecan: Phase 1/2 readout est. (NCT06788197)
DESCRIPTION:Trastuzumab rezetecan\, phase 1/2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: A Study of SHR-A1811 and Fulvestrant\, With or Without HS
 -10352\, in Locally Advanced or Metastatic Breast Cancer Patients\nEstimat
 ed primary completion: 31 March 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06788197
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07796763-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07796763)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Colorectal Cancer.\nStudy: A 
 Global Trial of Trastuzumab Rezetecan (SHR-A1811) in Combination With Chem
 otherapy and Bevacizumab as First-Line Treatment in Patients With Advanced
  Colorectal Cancer Expressing HER2\nEstimated primary completion: 1 May 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-rezet
 ecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07796763
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07949695-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07949695)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Breast Cancer.\nStudy: Neoadj
 uvant Trastuzumab Rezetecan Plus Toripalimab and Endocrine Therapy in HR-P
 ositive HER2-Low Breast Cancer\nEstimated primary completion: 31 May 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-rezeteca
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 949695
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06778031-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT06778031)
DESCRIPTION:Trastuzumab rezetecan\, phase 2.\nStudy: A Clinical Study of SH
 R-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic B
 iliary Tract Cancer\nEstimated primary completion: June 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06778031
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07497386-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07497386)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: A Trial of Trastuzumab Rezetecan in Unresectable Locally Re
 current/Metastatic Breast Cancer\nEstimated primary completion: June 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-rezeteca
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 497386
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07618923-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07618923)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Breast Cancer.\nStudy: Neoadj
 uvant Dalpiciclib + AI → SHR-A1811 for HR+/HER2-Low Breast Cancer\nEstim
 ated primary completion: June 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07618923
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07726433-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07726433)
DESCRIPTION:Trastuzumab rezetecan\, phase 2.\nStudy: Fosrolapitant Combined
  With Palonosetron to Prevent Trastuzumab Rezetecan Related CINV\nEstimate
 d primary completion: 1 June 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07726433
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07624201-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07624201)
DESCRIPTION:Trastuzumab rezetecan\, phase 2.\nStudy: Trastuzumab Rezetecan 
 and Adebrelimab as Neoadjuvant Therapy for HER2-Positive Muscle-Invasive B
 ladder Cancer\nEstimated primary completion: 1 June 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07624201
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07639983-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280605
DTEND;VALUE=DATE:20280606
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07639983)
DESCRIPTION:Trastuzumab rezetecan\, phase 2.\nStudy: Multi-Omics-Based Phas
 e Ⅱ Trial of Trastuzumab Rezetecan Plus Camrelizumab for Perioperative T
 herapy in HER2-Positive Muscle-Invasive Urothelial Carcinoma\nEstimated pr
 imary completion: 5 June 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07639983
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07037199-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07037199)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Efficacy and Safety of Trastuzumab Rezetecan Followed by CD
 K4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced B
 reast Cancer\nEstimated primary completion: 30 June 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07037199
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06666166-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT06666166)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Colorectal Cancer.\nStudy: SH
 R-A1811 Combined with Apatinib in the Treatment of Advanced Gastric or Gas
 troesophageal Junction Adenocarcinoma and Colorectal Cancer\nEstimated pri
 mary completion: July 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/trastuzumab-rezetecan#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06666166
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07241793-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07241793)
DESCRIPTION:Trastuzumab rezetecan\, phase 2.\nStudy: Phase II Study of Tras
 tuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Lo
 cally Advanced or Metastatic Urothelial Carcinoma (la/mUC)\nEstimated prim
 ary completion: 1 July 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/trastuzumab-rezetecan#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07241793
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07741448-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280815
DTEND;VALUE=DATE:20280816
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07741448)
DESCRIPTION:Trastuzumab rezetecan\, phase 2.\nStudy: Neoadjuvant Gemcitabin
 e Plus Trastuzumab Rezetecan in HER2-positive UTUC\nEstimated primary comp
 letion: 15 August 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/trastuzumab-rezetecan#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07741448
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07132242-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280830
DTEND;VALUE=DATE:20280831
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07132242)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, HER2-Positive Breast Cancer.\
 nStudy: SHR-A1811 Combine With Pyrotinib for Locally Advanced/Metastatic H
 ER2 Positive Breast Cancer\nEstimated primary completion: 30 August 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-rezetecan
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT071
 32242
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07177950-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Trastuzumab rezetecan: Phase 1/2 readout est. (NCT07177950)
DESCRIPTION:Trastuzumab rezetecan\, phase 1/2\, HER2-Positive Breast Cancer
 .\nStudy: A Two-cohort Study of SHR-A1811 in the Treatment of HER2-positiv
 e Breast Cancer With Brain Metastases\nEstimated primary completion: 30 Se
 ptember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuz
 umab-rezetecan#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07177950
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07817082-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07817082)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Phase II Study of SHR-A1811 for Ultra-Low HER2 Advanced Bre
 ast Cancer\nEstimated primary completion: 30 September 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07817082
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07843303-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07843303)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Ovarian Cancer.\nStudy: Trast
 uzumab Rezetecan Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian 
 Cancer\nEstimated primary completion: 30 September 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07843303
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07669610-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Trastuzumab rezetecan: Phase 3 readout est. (NCT07669610)
DESCRIPTION:Trastuzumab rezetecan\, phase 3\, Breast Cancer.\nStudy: An Ope
 n-Label\, Randomized Phase III Study of Trastuzumab Rezetecan With or With
 out Bevacizumab in First to Third Line BLIS Subtype TNBC\nEstimated primar
 y completion: 30 September 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07669610
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07760844-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Trastuzumab rezetecan: Phase 3 readout est. (NCT07760844)
DESCRIPTION:Trastuzumab rezetecan\, phase 3\, Breast Cancer.\nStudy: An Ope
 n-Label\, Randomized Phase III Study of Trastuzumab Rezetecan With or With
 out Everolimus in First to Third Line LAR Subtype TNBC\nEstimated primary 
 completion: 30 September 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07760844
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07317778-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20281015
DTEND;VALUE=DATE:20281016
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07317778)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Breast Cancer.\nStudy: Chemot
 herapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR
 +/HER2 Low Early Stage Breast Cancer\nEstimated primary completion: 15 Oct
 ober 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzuma
 b-rezetecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07317778
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07912957-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07912957)
DESCRIPTION:Trastuzumab rezetecan\, phase 2.\nStudy: Neoadjuvant SHR-A1811 
 ± Adebrelimab in GC/GEJ\nEstimated primary completion: 31 October 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-rezetecan#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0791
 2957
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07865611-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07865611)
DESCRIPTION:Trastuzumab rezetecan\, phase 2.\nStudy: Response-Guided Bladde
 r Preservation With Trastuzumab Rezetecan\, Adebrelimab\, and Concurrent B
 ladder Radiotherapy in HER2-Expressing Muscle-Invasive Bladder Cancer\nEst
 imated primary completion: December 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07865611
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05769010-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT05769010)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Study of SHR-A1811 in HER2-expression Advanced Breast Cance
 r With Brain Metastases\nEstimated primary completion: 30 December 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-rezetecan#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0576
 9010
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07340398-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07340398)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Breast Cancer.\nStudy: Neoadj
 uvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel\, Carboplati
 n\, Trastuzumab\, and Pyrotinib After Suboptimal Response to Neoadjuvant D
 ual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Earl
 y Breast Cancer\nEstimated primary completion: 31 December 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07340398
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07631884-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07631884)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetec
 an in the Treatment of HER2-Expressiong Advanced Solid Tumor\nEstimated pr
 imary completion: 31 December 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07631884
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07560475-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07560475)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Exploratory Study of SHR-A1811 Via Different Administration
  Routes in Patients\nEstimated primary completion: 31 December 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-rezetecan#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07560475
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07382687-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Trastuzumab rezetecan: Phase 3 readout est. (NCT07382687)
DESCRIPTION:Trastuzumab rezetecan\, phase 3\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Famitinib Combined With SHR-A1811\, Versus SHR-A1811 for CD
 K4/6 Inhibitors-resistent Advanced HR+/HER2- Breast Cancer With SNF4 Subty
 pe\nEstimated primary completion: 31 December 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07382687
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07589699-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Trastuzumab rezetecan: Phase 4 readout est. (NCT07589699)
DESCRIPTION:Trastuzumab rezetecan\, phase 4\, HER2-Positive Breast Cancer.\
 nStudy: Trastuzumab Rezetecan (T-DXh) in HER2+ Breast Cancer With Non-pCR 
 After TCbHP\nEstimated primary completion: 31 December 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07589699
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07417241-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07417241)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, HER2-Positive Breast Cancer.\
 nStudy: SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+
  Advanced Breast Cancer: A Randomized Study\nEstimated primary completion:
  31 January 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tra
 stuzumab-rezetecan#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07417241
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07699952-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07699952)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: First-line Therapy With Epidermal Growth Factor Receptor-Tyrosine K
 inase Inhibitor(EGFR-TKI) Combined With Trastuzumab Rezetecan for Advanced
  Non-small Cell Lung Cancer(NSCLC) Harboring EGFR Mutations Concomitant Wi
 th Human Epidermal Growth Factor Receptor 2(HER2) Alterations\nEstimated p
 rimary completion: March 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07699952
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07787338-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07787338)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, HER2-Positive Breast Cancer.\
 nStudy: SHR-A1811 Monotherapy or Sequential THPy as Neoadjuvant Therapy fo
 r Stage II-III HER2-Positive Breast Cancer\nEstimated primary completion: 
 April 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzum
 ab-rezetecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07787338
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07802288-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07802288)
DESCRIPTION:Trastuzumab rezetecan\, phase 2.\nStudy: Phase II Study of Tras
 tuzumab Rezetecan Combined With Retlirafusp Alfa With or Without CAPOX as 
 Perioperative Therapy for Resectable Locally Advanced Gastric/Gastroesopha
 geal Junction Adenocarcinoma\nEstimated primary completion: 30 April 2029.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-rezeteca
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 802288
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06927180-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20290501
DTEND;VALUE=DATE:20290502
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT06927180)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Breast Cancer.\nStudy: SHR-A1
 811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC\nEsti
 mated primary completion: 1 May 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06927180
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07647263-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07647263)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, HER2-Positive Breast Cancer.\
 nStudy: Trastuzumab Rezetecan Neoadjuvant Therapy in THP-Insensitive HER2-
 Positive Early Breast Cancer\nEstimated primary completion: June 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-rezetecan#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076472
 63
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07377916-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Trastuzumab rezetecan: Phase na readout est. (NCT07377916)
DESCRIPTION:Trastuzumab rezetecan\, phase na\, Non-Small Cell Lung Cancer.\
 nStudy: Clinical Study of SHR-A1811 Combined With Pertuzumab as Second-Lin
 e Therapy in Patients With HER2-Altered Advanced NSCLC\nEstimated primary 
 completion: 30 June 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/trastuzumab-rezetecan#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07377916
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06881017-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20290801
DTEND;VALUE=DATE:20290802
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT06881017)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Gastric Cancer.\nStudy: Estab
 lishment of Precision Targeted Therapy Strategies for Advanced Gastric Can
 cer Based on Novel Molecular Subtyping\nEstimated primary completion: 1 Au
 gust 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzuma
 b-rezetecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06881017
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07781202-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20290830
DTEND;VALUE=DATE:20290831
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07781202)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: A Multicenter\, Single-Arm\, Prospective Phase II Clinical Study of
  Trastuzumab Rezetecan Combined With Radiotherapy in Patients With HER2-Mu
 tated Oligoprogressive Advanced Non-Small Cell Lung Cancer\nEstimated prim
 ary completion: 30 August 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07781202
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07676162-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Trastuzumab rezetecan: Phase 3 readout est. (NCT07676162)
DESCRIPTION:Trastuzumab rezetecan\, phase 3\, Colorectal Cancer.\nStudy: A 
 Clinical Study of SHR-A1811 in Combination With Chemotherapy and Bevacizum
 ab Versus Standard Therapy as First-Line Treatment for Advanced Colorectal
  Cancer\nEstimated primary completion: September 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07676162
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07836543-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07836543)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: Trastuzumab Rezetecan and Adebrelimab\, Alone or in Combination\, A
 fter Chemoradiotherapy for HER2-Altered Unresectable Stage III Lung Cancer
 \nEstimated primary completion: December 2029. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07836543
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07926477-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07926477)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Colorectal Cancer.\nStudy: Tr
 astuzumab Rezetecan + Bevacizumab vs. TAS-102 + Bevacizumab in Pretreated 
 mCRC With HER2 Low/Moderate Expression or HER2 Positivity With RAS/BRAF Mu
 tation\nEstimated primary completion: 1 December 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07926477
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06126640-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Trastuzumab rezetecan: Phase 3 readout est. (NCT06126640)
DESCRIPTION:Trastuzumab rezetecan\, phase 3\, Breast Cancer.\nStudy: A Phas
 e III\, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine 
 (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual 
 Invasive Disease Following Neoadjuvant Therapy\nEstimated primary completi
 on: April 2030. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trast
 uzumab-rezetecan#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06126640
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07833657-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07833657)
DESCRIPTION:Trastuzumab rezetecan\, phase 2.\nStudy: Combined Intrathecal a
 nd Systemic Therapy With Trastuzumab Rezetecan for Leptomeningeal Metastas
 es\nEstimated primary completion: June 2030. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07833657
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06990516-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Trastuzumab rezetecan: Phase 1/2 readout est. (NCT06990516)
DESCRIPTION:Trastuzumab rezetecan\, phase 1/2\, Ovarian Cancer.\nStudy: SHR
  - A1811 Injection in the Treatment of Platinum-sensitive Recurrent Ovaria
 n Cancer\nEstimated primary completion: 1 June 2030. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06990516
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06990503-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Trastuzumab rezetecan: Phase 3 readout est. (NCT06990503)
DESCRIPTION:Trastuzumab rezetecan\, phase 3\, Ovarian Cancer.\nStudy: SHR -
  A1811 Versus Chemotherapy for Platinum-resistant Recurrent Epithelial Ova
 rian Cancer\nEstimated primary completion: 1 June 2030. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06990503
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07203729-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20300615
DTEND;VALUE=DATE:20300616
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07203729)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811
 ) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral
  Crisis\nEstimated primary completion: 15 June 2030. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07203729
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07118527-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Trastuzumab rezetecan: Phase 3 readout est. (NCT07118527)
DESCRIPTION:Trastuzumab rezetecan\, phase 3.\nStudy: A Phase III Study of S
 HR-A1811 in Combination With Chemotherapy and Adebrelimab in Previously Un
 treated Patients With Gastric or Gastroesophageal Junction Adenocarcinoma\
 nEstimated primary completion: October 2030. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07118527
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07679360-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Trastuzumab rezetecan: Phase 3 readout est. (NCT07679360)
DESCRIPTION:Trastuzumab rezetecan\, phase 3\, Breast Cancer.\nStudy: A Stud
 y of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investig
 ator's Choice of Therapy in Subjects With Residual Triple Negative Breast 
 Cancer\nEstimated primary completion: December 2030. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07679360
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07179939-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20301230
DTEND;VALUE=DATE:20301231
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07179939)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, HER2-Positive Breast Cancer.\
 nStudy: Maintenance Therapy in HER2-Positive Unresectable Locally Recurren
 t or Metastatic Breast Cancer: A Phase II Study\nEstimated primary complet
 ion: 30 December 2030. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/trastuzumab-rezetecan#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07179939
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07896005-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20310228
DTEND;VALUE=DATE:20310301
SUMMARY:Trastuzumab rezetecan: Phase 3 readout est. (NCT07896005)
DESCRIPTION:Trastuzumab rezetecan\, phase 3\, Non-Small Cell Lung Cancer.\n
 Study: A Study of SHR-A1811 Combined With Adebrelimab for the First-line H
 ER2-overexpressing Non-squamous Non-small Cell Lung Cancer\nEstimated prim
 ary completion: February 2031. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07896005
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07630103-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20310630
DTEND;VALUE=DATE:20310701
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07630103)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Efficacy and Safety of Trastuzumab Rezetecan or Trastuzumab
  Deruxtecan in Advanced Breast Cancer\nEstimated primary completion: June 
 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-rez
 etecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07630103
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07935226-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20311215
DTEND;VALUE=DATE:20311216
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07935226)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Induction Trastuzumab Rezetecan Followed by Maintenance Dal
 piciclib and Endocrine Therapy as First-line Treatment of HR+/HER2 Low mBC
 \nEstimated primary completion: 15 December 2031. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07935226
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07600164-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20311230
DTEND;VALUE=DATE:20311231
SUMMARY:Trastuzumab rezetecan: Phase 4 readout est. (NCT07600164)
DESCRIPTION:Trastuzumab rezetecan\, phase 4\, HER2-Positive Breast Cancer.\
 nStudy: Real-world Study of Pyrotinib-containing Regimens of Advanced HER2
 -positive Breast Cancer\nEstimated primary completion: 30 December 2031. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-rezetecan#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0760
 0164
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07766772-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07766772)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, HER2-Positive Breast Cancer.\
 nStudy: Trastuzumab Rezetecan Followed by Pyrotinib\, and Trastuzumab Comb
 ined With Capecitabine as First-line Treatment for Advanced HER2-positive 
 Breast Cancer\nEstimated primary completion: 31 December 2031. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07766772
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07856303-9096@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20320831
DTEND;VALUE=DATE:20320901
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07856303)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, HER2-Positive Breast Cancer.\
 nStudy: SHR-A1811 Versus Trastuzumab Plus Pertuzumab in ctDNA-Positive HER
 2-Positive Early Breast Cancer After Pathologic Complete Response\nEstimat
 ed primary completion: August 2032. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07856303
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
